Breaking News Instant updates and real-time market news.

ATNM

Actinium Pharmaceuticals

$0.30

0.0044 (1.51%)

, NVS

Novartis

$82.79

0.17 (0.21%)

08:15
05/07/19
05/07
08:15
05/07/19
08:15

Actinium appoints Niva Almaula as Chief Business Officer

Actinium Pharmaceuticals (ATNM) announced the appointment of Niva Almaula, as Chief Business Officer, effective immediately. Almaula joins Actinium with significant experience in the targeted radiotherapy field, having most recently worked as Head, Business Development at Advanced Accelerator Applications, a nuclear medicine company acquired by Novartis (NVS) for $3.9B in January 2018. As Chief Business Officer, Almaula will be focused on leading partnership, licensing and collaboration activities for Actinium's clinical-stage ARC's or Antibody Radiation Conjugates for targeted conditioning including Iomab-B, Actimab-MDS and the Iomab-ACT program, its ARC therapeutics and combinations and AWE or Antibody Warhead Enabling technology platform that is being utilized in a collaborative research partnership by Astellas Pharma (ALPMY).

ATNM

Actinium Pharmaceuticals

$0.30

0.0044 (1.51%)

NVS

Novartis

$82.79

0.17 (0.21%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

  • 08

    May

  • 10

    May

  • 23

    May

  • 31

    May

ATNM Actinium Pharmaceuticals
$0.30

0.0044 (1.51%)

07/12/18
RILY
07/12/18
NO CHANGE
Target $3
RILY
Buy
Actinium price target raised to $3 from $2.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for Actinium Pharmaceuticals to $3.00 from $2.75 and keeps a Buy rating on the shares. The company's new Phase I trial for Actimab-A MRDexpands its footprint in acute myeloid leukemia, Zavoico tells investors in a research note.
NVS Novartis
$82.79

0.17 (0.21%)

04/25/19
04/25/19
UPGRADE

Buy
Novartis upgraded to Buy from Neutral at Guggenheim
As previously reported, Guggenheim analyst Seamus Fernandez upgraded Novartis to Buy with a price target of CHF95, saying he is more confient that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. The analyst notes that investors have an "attractive opportunity" given the company's "structural shift in operating margins driven by transformational SMA gene therapy, Zolgensma, a best-case Mayzent label in MS, and several near-term pipeline catalysts."
04/25/19
04/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying while 2019 remains a year of transition, Facebook management has now produced multiple quarters of better than expected revenue and earnings. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Betsy Graseck saying she believes its strong revenue growth remains intact given its record growth in proprietary cards, strong contribution from Millennials, fee-based products and its strong loan and transactional growth. 3. Novartis (NVS) upgraded to Buy from Neutral at Guggenheim with analyst Seamus Fernandez saying he is more confident that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. 4. Sirius XM (SIRI) upgraded to Buy from Hold at Pivotal Research with analyst Jeffrey Wlodarczak saying yesterday's post-earnings selloff was overdone as investors overreacted to slightly lower than expected new car installations and modestly lower than expected self-pay net subscriber additions. 5. General Dynamics (GD) upgraded to Neutral from Underweight at JPMorgan with analyst Seth Seifman saying General Dynamics has underperformed the market by~21% since the start of 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/19
WELS
05/01/19
NO CHANGE
Target $18
WELS
Market Perform
Teva shares reflect much of bad news, says Wells Fargo
Wells Fargo analyst David Morris kept his Market Perform rating and $18 price target on Teva (TEVA) ahead of its Q1 earnings tomorrow, saying investors have "low expectations" for the quarter after "weak-ish" Sandoz results from Novartis (NVS). The analyst also points to IQVIA (IQV) sales and prescriptions data indicating that Teva generic sales were down 12% in March, 10% in February, and 13% in January, though the decline are "much smaller" than seen in U.S. generics during 2018. Morris further expects Teva to address the risk of opioid litigation that became a concern during the quarter in its earnings call.
05/02/19
FBCO
05/02/19
INITIATION
Target $66
FBCO
Outperform
Alcon initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic started coverage of Alcon (ALC) with an Outperform rating and a $66 price target. Recently spun off from parent Novartis (NVS), Alcon is now positioned to deliver improving growth and margins, the analyst contends. Miksic believes the key to the Alcon investment case is the opportunity to increase revenue growth and margins through expanded market share and its leadership positions in cataract, retinal surgery, contact lenses and consumer eye care.
ALPMY Astellas Pharma
$0.00

(0.00%)

06/08/18
GSCO
06/08/18
DOWNGRADE
GSCO
Neutral
Astellas Pharma downgraded to Neutral from Buy at Goldman Sachs
06/08/18
GSCO
06/08/18
DOWNGRADE
GSCO
Neutral
Goldman downgrades Astellas to Neutral with Xtandi growth priced in
Goldman Sachs analyst Akinori Ueda downgraded Astellas Pharma (ALPMY) to Neutral from Buy. Renewed appreciation for Xtandi's growth potential as well as Astellas' "proactive stance" on shareholder returns are largely priced into the stock, Ueda tells investors in a research note. With Japan Healthcare, the analyst prefers Santen Pharmaceutical, Shionogi and Sawai Pharmaceutical.
09/13/18
DBAB
09/13/18
DOWNGRADE
DBAB
Hold
Astellas Pharma downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Joseph Cairnes downgraded Astellas Pharma to Hold with an unchanged price target of JPY 2,020. The analyst sees a more balanced risk/reward at current valuation levels.
11/05/18
JPMS
11/05/18
DOWNGRADE
JPMS
Underweight
Astellas Pharma downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Naomi Kumagai downgraded Astellas Pharma to Underweight and lowered her price target for the shares to 1,400 yen from 1,600 yen. The analyst sees "many causes for concern."

TODAY'S FREE FLY STORIES

UBER

Uber

$40.46

-0.63 (-1.53%)

19:17
05/23/19
05/23
19:17
05/23/19
19:17
Periodicals
Uber to roll out JUMP electric bike service in London, Reuters says »

Uber will bring its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

AMZN

Amazon.com

$1,815.30

-42.44 (-2.28%)

19:07
05/23/19
05/23
19:07
05/23/19
19:07
Hot Stocks
Amazon launches support for traditional Chinese books on Kindle »

Amazon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 25

    Jun

LM

Legg Mason

$36.91

-0.25 (-0.67%)

19:00
05/23/19
05/23
19:00
05/23/19
19:00
Periodicals
Legg Mason to cut 12% of its workforce, FT reports »

Legg Mason plans to cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGTX

TG Therapeutics

$7.12

0.22 (3.19%)

18:57
05/23/19
05/23
18:57
05/23/19
18:57
Hot Stocks
TG Therapeutics CEO: We're a bit of an unconventional company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

SQM

SQM

$30.86

-1.82 (-5.57%)

18:57
05/23/19
05/23
18:57
05/23/19
18:57
Downgrade
SQM rating change at BMO Capital »

SQM downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SQM

SQM

$30.86

-1.82 (-5.57%)

18:51
05/23/19
05/23
18:51
05/23/19
18:51
Downgrade
SQM rating change  »

SQM downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

VSAT

ViaSat

$87.89

-1.63 (-1.82%)

, DECK

Deckers Brands

$147.27

-2.94 (-1.96%)

18:50
05/23/19
05/23
18:50
05/23/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Viasat…

VSAT

ViaSat

$87.89

-1.63 (-1.82%)

DECK

Deckers Brands

$147.27

-2.94 (-1.96%)

DXC

DXC Technology

$52.00

-2.5 (-4.59%)

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

INTU

Intuit

$241.30

-6.22 (-2.51%)

NVCR

Novocure

$49.40

-1.92 (-3.74%)

CTL

CenturyLink

$9.66

-0.29 (-2.91%)

ADSK

Autodesk

$169.64

-4.47 (-2.57%)

LGF.A

Lionsgate

$15.96

-0.06 (-0.37%)

ROST

Ross Stores

$94.54

-0.06 (-0.06%)

SPLK

Splunk

$128.68

-7.12 (-5.24%)

HPE

HP Enterprise

$14.33

-0.21 (-1.44%)

DVAX

Dynavax

$6.36

(0.00%)

RTIX

RTI Surgical

$4.40

-0.08 (-1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 10

    Jun

  • 12

    Jun

  • 13

    Jun

  • 17

    Jun

  • 09

    Jul

EPE

EP Energy

$0.16

(0.00%)

18:32
05/23/19
05/23
18:32
05/23/19
18:32
Hot Stocks
EP Energy suspends NYSE trading, begins trading on OTC markets »

EP Energy confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$76.07

-0.28 (-0.37%)

, NFLX

Netflix

$352.23

-7.47 (-2.08%)

18:15
05/23/19
05/23
18:15
05/23/19
18:15
Hot Stocks
T-Mobile says new Magenta plan will include Netflix Basic for families »

T-Mobile (TMUS) said…

TMUS

T-Mobile

$76.07

-0.28 (-0.37%)

NFLX

Netflix

$352.23

-7.47 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 13

    Jun

  • 25

    Jun

HOPE

Hope Bancorp

$13.23

-0.5 (-3.64%)

18:06
05/23/19
05/23
18:06
05/23/19
18:06
Hot Stocks
Hope Bancorp names Kevin S. Kim chairman of the board »

Hope Bancorp, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CTL

CenturyLink

$9.66

-0.29 (-2.91%)

18:06
05/23/19
05/23
18:06
05/23/19
18:06
Hot Stocks
CenturyLink CEO buys 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXR

Extra Space Storage

$106.85

0.59 (0.56%)

18:00
05/23/19
05/23
18:00
05/23/19
18:00
Hot Stocks
Extra Space Storage raises quarterly dividend by 4.7% to 90c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 04

    Jun

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

17:58
05/23/19
05/23
17:58
05/23/19
17:58
Hot Stocks
HP Inc. says continue to expect FY19 free cash flow of at least $3.7B »

Guidance from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

17:57
05/23/19
05/23
17:57
05/23/19
17:57
Hot Stocks
HP Inc CFO sees FY19 tax rate of about 19% »

Says FY19 EPS outlook of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

BA

Boeing

$350.57

-1.93 (-0.55%)

17:56
05/23/19
05/23
17:56
05/23/19
17:56
Periodicals
FAA tells U.N. it sees 737 MAX approval as soon as late June, Reuters says »

FAA representatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

BA

Boeing

$350.57

-1.93 (-0.55%)

, UAL

United Continental

$80.91

-0.94 (-1.15%)

17:52
05/23/19
05/23
17:52
05/23/19
17:52
Periodicals
Airlines see 737 MAX needing 100-150 hours of preparation, Reuters says »

Officials from three U.S.…

BA

Boeing

$350.57

-1.93 (-0.55%)

UAL

United Continental

$80.91

-0.94 (-1.15%)

AAL

American Airlines

$29.49

-0.43 (-1.44%)

LUV

Southwest

$50.97

-1.6 (-3.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 25

    Jul

  • 13

    Nov

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

17:50
05/23/19
05/23
17:50
05/23/19
17:50
Hot Stocks
HP Inc CFO says continued to 'outperform PC market and gain profitable share' »

Says commercial portfolio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

TCCO

Technical Comm Corp

$3.48

(0.00%)

17:48
05/23/19
05/23
17:48
05/23/19
17:48
Hot Stocks
Technical Comm Corp receives compliance and plan acceptance notices from Nasdaq »

Technical Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

17:42
05/23/19
05/23
17:42
05/23/19
17:42
Hot Stocks
HP Inc. says PC growth across industry was subdued this quarter »

Continue to gain momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

RST

Rosetta Stone

$24.93

1.135 (4.77%)

17:38
05/23/19
05/23
17:38
05/23/19
17:38
Hot Stocks
Rosetta Stone officer Sonia Galindo sells over $107K in company shares »

Rosetta Stone officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

CCF

Chase Corporation

$100.72

0.32 (0.32%)

17:32
05/23/19
05/23
17:32
05/23/19
17:32
Hot Stocks
Chase Corporation chairman sells 2K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNR

RenaissanceRe

$170.85

-0.34 (-0.20%)

17:24
05/23/19
05/23
17:24
05/23/19
17:24
Syndicate
Breaking Syndicate news story on RenaissanceRe »

RenaissanceRe files $750M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTIX

RTI Surgical

$4.40

-0.08 (-1.79%)

17:21
05/23/19
05/23
17:21
05/23/19
17:21
Syndicate
Breaking Syndicate news story on RTI Surgical »

RTI Surgical files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 17

    Jun

DXC

DXC Technology

$52.00

-2.5 (-4.59%)

17:21
05/23/19
05/23
17:21
05/23/19
17:21
Earnings
DXC Technology sees FY20 adjusted EPS $7.75-$8.50, consensus $9.21 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

RTIX

RTI Surgical

$4.40

-0.08 (-1.79%)

17:19
05/23/19
05/23
17:19
05/23/19
17:19
Syndicate
Breaking Syndicate news story on RTI Surgical »

RTI Surgical files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 17

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.